In addition, conjugates 2, 3 and 5 showed similar antitumor activity against HT-29 cells in vitro as the previously prepared GnRH-III–Dau conjugate [42] that had significant and better in vivo tumor growth inhibition effect compared to the free drug [36]. This evidence concerns the gene GNRH1 and neoplasm.